UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008‐2011)

Hepatology (Baltimore, Md.), 2016-03, Vol.63 (3), p.776-786

2016

Volltextzugriff (PDF)

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease

Nature communications, 2020-05, Vol.11 (1), p.2127-11, Article 2127

2020

Volltextzugriff (PDF)

Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk

The American journal of gastroenterology, 2020-04, Vol.115 (4), p.584-595

2020

Volltextzugriff (PDF)

Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition

Autophagy, 2017-10, Vol.13 (10), p.1767-1781

2017

Volltextzugriff (PDF)

Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)

BMC medicine, 2022-03, Vol.20 (1), p.93-93, Article 93

2022

Volltextzugriff (PDF)

Sodium‐glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter‐organ crosstalk

Diabetes, obesity & metabolism, 2019-04, Vol.21 (4), p.801-811

2019

Volltextzugriff (PDF)

Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study

Metabolism, clinical and experimental, 2024-03, Vol.152, p.155789-155789, Article 155789

2024

Volltextzugriff (PDF)

Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis

Diabetes and Metabolism Journal, 2019, 43(1), 171, pp.31-45

2019

Volltextzugriff (PDF)

MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study

Journal of gastroenterology and hepatology, 2023-09, Vol.38 (9), p.1598-1609

2023

Volltextzugriff (PDF)

Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease

Gut and Liver, 2022, 16(2), , pp.290-299

2022

Volltextzugriff (PDF)

Nonalcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2021-04, Vol.23 (4), p.1041-1051

2021

Volltextzugriff (PDF)

Risk of Incident Dementia According to Metabolic Health and Obesity Status in Late Life: A Population-Based Cohort Study

The journal of clinical endocrinology and metabolism, 2019-07, Vol.104 (7), p.2942-2952

2019

Volltextzugriff (PDF)

Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo‐controlled, double‐blind, multicenter trial

Journal of diabetes investigation, 2016-05, Vol.7 (3), p.366-373

2016

Volltextzugriff (PDF)

Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial

Diabetes, obesity & metabolism, 2018-10, Vol.20 (10), p.2408-2415

2018

Volltextzugriff (PDF)

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus

Diabetes and Metabolism Journal, 2021, 45(3), 185, pp.326-336

2021

Volltextzugriff (PDF)

The effects of the voglibose on non-alcoholic fatty liver disease in mice model

Scientific reports, 2022-08, Vol.12 (1), p.13595-13595, Article 13595

2022

Volltextzugriff (PDF)

Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies

Scientific reports, 2016-04, Vol.6 (1), p.24013-24013, Article 24013

2016

Volltextzugriff (PDF)

Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial

Journal of clinical medicine, 2020-01, Vol.9 (1), p.259

2020

Volltextzugriff (PDF)

Metformin Restores Parkin-Mediated Mitophagy, Suppressed by Cytosolic p53

International journal of molecular sciences, 2016-01, Vol.17 (1), p.122-122

2016

Volltextzugriff (PDF)

Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease

Gut and Liver, 2022, 16(5), , pp.786-797

2022

Volltextzugriff (PDF)

Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression

Scientific reports, 2020-11, Vol.10 (1), p.19429-19429, Article 19429

2020

Volltextzugriff (PDF)

Waist‐to‐calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes

Journal of gastroenterology and hepatology, 2018-05, Vol.33 (5), p.1082-1091

2018

Volltextzugriff (PDF)

Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease

Hepatobiliary & pancreatic diseases international, 2022-06, Vol.21 (3), p.241-247

2022

Volltextzugriff (PDF)

Efficacy and safety of fixed‐dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double‐blind, controlled, phase 3 trial

Diabetes, obesity & metabolism, 2019-01, Vol.21 (1), p.103-111

2019

Volltextzugriff (PDF)

Gamma glutamyltransferase and risk of dementia in prediabetes and diabetes

Scientific reports, 2020-04, Vol.10 (1), p.6800-6800, Article 6800

2020

Volltextzugriff (PDF)

1 – 25 von 510

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(432)
Mit Volltextzugriff
(450)

Publikationsform

Sprache

Englisch
(403)
Koreanisch
(101)
Japanisch
(5)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008‐2011)

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease

Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk

Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition

Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)

Sodium‐glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter‐organ crosstalk

Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study

Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis

MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study

Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetes

Risk of Incident Dementia According to Metabolic Health and Obesity Status in Late Life: A Population-Based Cohort Study

Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo‐controlled, double‐blind, multicenter trial

Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus

The effects of the voglibose on non-alcoholic fatty liver disease in mice model

Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies

Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial

Metformin Restores Parkin-Mediated Mitophagy, Suppressed by Cytosolic p53

Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease

Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression

Waist‐to‐calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes

Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease

Efficacy and safety of fixed‐dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double‐blind, controlled, phase 3 trial

Gamma glutamyltransferase and risk of dementia in prediabetes and diabetes

Suchergebnisse filtern